PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
10. Juni 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its...
PAVmed Launches Digital Health Company Veris Health Inc.
02. Juni 2021 09:30 ET
|
PAVmed Inc.
New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and...
PAVmed Provides Business Update and First Quarter 2021 Financial Results
17. Mai 2021 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
29. April 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that...
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
10. März 2021 09:30 ET
|
PAVmed Inc.
On-demand corporate presentation scheduled for March 17, 2021 NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Retires Convertible Debt
03. März 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
01. März 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVmed Announces Closing of its Public Offering of Common Stock
25. Februar 2021 12:37 ET
|
PAVmed Inc.
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Announces Proposed Public Offering of Common Stock
22. Februar 2021 16:13 ET
|
PAVmed Inc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
22. Februar 2021 08:18 ET
|
PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...